🚀 Apply for £10k+ grants with our Startup Launch Kit
shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development (Cooperative Agreement, Clinical Trial Optional)

    NOT-DK-26-313

    Norann Zaghloul, PhD National Institute of Diabetes and Digestive and Kidney Diseases

    Opening date 17 Jun 2025, 12:00AM

    Closing date N/A

    Funding Opportunity Number: NOT-DK-26-313

    Opportunity Category: Discretionary

    Expected Number of Awards: 1

    CFDA Number(s): 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research

    Cost Sharing or Matching Requirement: No

    Posted Date: Jun 17, 2025 12:00:00 AM EDT

    Closing Date: N/A

    Estimated Total Program Funding: 3000000

    Eligible Applicants: Public and State controlled institutions of higher education,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Small businesses,County governments,Public housing authorities/Indian housing authorities,Private institutions of higher education,For profit organizations other than small businesses,Special district governments,Native American tribal governments (Federally recognized),State governments,Native American tribal organizations (other than Federally recognized tribal governments),Independent school districts

    Additional Information on Eligibility: Indian/Native American Tribal Governments (Other than Federally Recognized); Eligible Agencies of the Federal Government; U.S. Territory or Possession; Faith-based or Community-based Organizations; Regional Organizations

    Description:

    The Accelerating Medicines Partnership (AMP), is a pre-competitive collaboration among government, academia, and industry to improve the ongoing efforts to develop new therapies for complex, heterogeneous diseases (http://www.nih.gov/science/amp/). The overarching goal of AMP CMD is to use human genetics as a powerful approach to obtain human-data derived disease understanding and biomarker/therapeutic opportunities. This is being accomplished through systematic aggregation of existing genotype-phenotype data for CMD, related traits, and its complications as well as the generation of a large amount of new omic data. The goal of the NIDDK-funded component of the consortium is to aid in advancing the understanding of the mechanisms responsible for T2D development through the integration of large-scale genetic data that will contribute to further deconstruction of the pathophysiology of T2D, and potentially of its major complications, including macrovascular and microvascular disease. The purpose of this is to request is for renewal of the AMP CMD UM1 program for another 5 years for the portal to aggregate and collate data on T2D/CMD genes and their functional variants so that it can be queried by the scientific community.

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept